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Abstract 
Prospective studies have shown equal outcomes after mastectomy or breast conservation in patients with 
invasive breast cancer; however, many of these studies excluded elderly patients. We identified patients in their 
eighties and nineties with clinical stage 0 to II breast cancer undergoing mastectomy or lumpectomy with or without 
radiation from the prospective sentinel lymph node (SLN) database at Wake Forest Baptist Health and analyzed 
their treatment and survival. Of 92 patients, 24 (26.1%) underwent mastectomy, 22 (23.9%) lumpectomy with 
radiation, and 46 (50.0%) lumpectomy alone. Significant differences were noted in tumor size (p=0.018), nodal 
status (p=0.013), and stage (p=0.011) across the groups. Only 7.6% of patients had chemotherapy, while 65.3% took 
anti-estrogen therapy. Recurrence occured in 11 (12.0%) patients. In univariate analysis, overall survival did not 
differ by surgery. Age was the only factor that increased risk of death (HR=1.19, p=0.028). Neither tumor factors 
nor type of local treatment significantly influenced overall survival. Octogenarians and nonagenarians with early-
stage breast cancer undergoing breast-conserving surgery with or without radiation have equivalent survival to 
patients having a mastectomy.  
 
Breast cancer disproportionately affects older women with regards to incidence and rate of mortality.1 This 
is important as the US population is aging and living longer.2 While women age 80 years and older account for only 
4% of the US population, they made up over 12% of the 230,000 new breast cancer diagnoses and 25% of the 
40,000 breast cancer-related deaths in 2015.2-3  
Prospective studies have shown equal survival outcomes after mastectomy and breast-conserving therapy in 
patients with invasive breast cancer, however, many of these studies excluded women 80 years and older.4-6 Breast 
cancers in these elderly patients tend to be less aggressive, as they are more likely to be hormone receptor (HR)-
positive, human epidermal growth factor receptor 2 (HER2/neu)-negative, and low grade.7-11 Despite favorable 
tumor biology, elderly women 80 years and older often present with more advanced disease, larger tumors with 
nodal spread, and have a higher risk of dying from breast cancer.7-8, 10-13 This may be related to decreased screening 
in this age group.13 
Historically, treatment of breast cancer in elderly patients tends to be less aggressive than for younger 
patients.8, 14 The elderly are less likely to receive surgical resection, axillary nodal staging, adjuvant radiation 
therapy, hormone therapy, chemotherapy, or they are given non-guideline chemotherapy.7-10, 12, 15-17 Age, comorbid 
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conditions, lack of evidence-based treatment of breast cancer in the elderly population, less aggressive biological 
nature of breast cancer, patient and provider bias, psychosocial issues, and diminished functional status are all cited 
as reasons for undertreatment in this population, however, studies vary on the degree of impact this undertreatment 
plays on recurrence and survival.10, 14-15, 18-22 
Prior analysis of a large national contemporary population-based dataset performed at our institution 
demonstrated that survival in women 70 years and older with early-stage invasive breast cancer is not dependent on 
type of local treatment but rather on tumor-specific variables and nodal disease, making assessment of lymph node 
status important in this age group.18 The purpose of the current study was to review the local treatment and 
outcomes of octogenarians and nonagenarians treated for early-stage breast cancer at our institution. We also looked 
at the use and adherence to adjuvant anti-estrogen therapy in these elderly patients. 
Materials and Methods 
Patient Cohort 
After Institutional Review Board approval, we conducted a retrospective cohort study of the prospectively 
maintained sentinel lymph node (SLN) database at Wake Forest Baptist Health. This database captures all patients 
who undergo SLN mapping in the operating room. We also reviewed our individual breast surgeon’s databases to 
capture additional patients who met inclusion criteria but may not have undergone SLN mapping. We identified all 
patients 80 years of age and older who underwent surgical treatment of breast cancer at Wake Forest Baptist Health 
between January 1, 2005 and December 31, 2015. We included only patients with clinical stage 0 to II node-
negative breast cancer. We excluded patients with benign, stage III, and stage IV disease.  
Study Variables and Definitions 
From the medical record, we collected the following data: age, race, tumor size, nodal status, method of 
diagnosis, hormone receptor status, local treatment (lumpectomy or mastectomy), SLN biopsy, axillary lymph node 
dissection (ALND), radiation therapy (XRT), receipt of anti-estrogen therapy, chemotherapy, and trastuzumab 
administration. Tumor size and nodal status were evaluated by pathologic examination of the final surgical 
specimen. The method of diagnosis included a palpable mass on physical exam, mammogram, ultrasound, and 
computed tomography (CT) scan. Estrogen and progesterone receptors were considered positive if greater than 1% 
of nuclei were involved. Her2/neu receptor was considered positive if greater than 1% of the membrane was 
involved. The primary outcomes of interest were the incidence of locoregional recurrence, distant metastasis, and 
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breast cancer-specific survival. The secondary outcomes were adherence to anti-estrogen therapy, reasons for 
nonadherence, and SLN positivity. Adherence was defined as completion of five years of anti-estrogen therapy 
(tamoxifen, aromatase inhibitor, or combination of the two) as recommended by the National Comprehensive 
Cancer Network or continued use of anti-estrogen therapy at the time of study completion.23 Patients who did not 
start anti-estrogen therapy were excluded from analysis of adherence to recommended treatment. 
Statistical Analysis 
Demographic and tumor characteristics were summarized overall and by stage and treatment type. 
Descriptive data are presented as median and frequency. Differences in medians and frequencies were assessed 
using Chi square and Fisher’s exact tests. Univariate Cox regression models were used to predict factors associated 
with breast cancer-specific death. All statistical analyses were conducted using SPSS software, Version 19.0 (IBM 
Corp., Somers, NY) and SAS, Version 9.4 (SAS Institute, Inc., Cary, NC), and a 0.05 significance level was used 
throughout the analysis. 
Results 
Patient and Tumor Characteristics 
We identified 92 eligible women with clinical stage 0 to II node-negative breast cancer who underwent 
surgical resection at Wake Forest Baptist Health during the eleven-year study period. Median age was 82 years 
(range 80 to 94 years) (Table 1). After final histology from the surgical specimen and evaluation of axillary lymph 
nodes, 10 patients (10.9%) had stage 0 disease, 53 (57.6%) stage I, 19 (20.7%) stage II, and 10 (10.9%) stage III 
invasive breast cancer (Figure 1). Eighty-one patients (88.0%) were white, ten (10.9%) black, and one (1.1%) other 
(Hispanic ethnicity). Thirty-four cancers (37.0%) were diagnosed after a palpable mass was detected by the patient 
or provider, but the majority were diagnosed via imaging, with 54 (58.7%) by mammogram, three (3.3%) by 
ultrasound, and one (1.1%) by CT scan. 
Twenty-four patients (26.1%) underwent mastectomy, 22 (23.9%) lumpectomy with radiation, and 46 
(50.0%) lumpectomy alone (Table 2, Figure 2). There was a significant difference in the type of surgery by stage (p 
= 0.011), with the vast majority of lumpectomy alone performed for stage I disease (Table 2). The majority of 
patients had ER-positive (78.3%) and Her2/neu-negative (82.6%) tumors. SLN biopsies were performed in 78 
patients (84.8%). Fourteen patients (15.2%) did not undergo SLN mapping. The use of SLN mapping did not differ 
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significantly by type of surgery (p = 0.265). Of those who underwent SLN biopsy, the SLN was positive in 19 
patients (24.4%). ALND was performed in 15 patients (16.3%). 
Of the 72 patients who had ER-positive tumors, 47 patients (65.3%) received anti-estrogen therapy; 15 
received tamoxifen, 37 received an aromatase inhibitor (AI), and 5 patients received both. None of the 20 patients 
(21.7%) with an ER-negative tumor received tamoxifen or an AI. Of the 47 patients who received tamoxifen or an 
AI, only 21 patients (44.7%) adhered to a five-year course or were still taking anti-estrogen therapy at the time of 
study completion. Reasons for nonadherence were adverse side effects (84.6%), disease progression or development 
of endometrial thickening or a second malignancy (11.5%), and financial constraints (3.9%) (Table 3). Sixteen 
patients (17.4%) were Her2/neu receptor-positive. Of these, five (31.3%) received trastuzumab. Chemotherapy was 
given to seven patients in the overall cohort (7.6%). Eleven patients (12.0%) had a recurrence of their breast cancer, 
of which five developed locoregional recurrence and six developed distant metastasis (Figure 3). There was no 
difference in locoregional recurrence (p=0.414) or distant metastasis (p=0.697) between the three local treatment 
groups (mastectomy, lumpectomy with radiation, or lumpectomy alone). There was also no difference in 
locoregional recurrence (p=0.221) or distant metastasis (p=0.437) when looking only at patients who underwent 
lumpectomy with radiation versus lumpectomy alone. Three patients (3.3%) in the cohort died a breast cancer-
related death. Of those who died, two had undergone a mastectomy and one a lumpectomy with radiation. There was 
no significant difference in death due to breast cancer between the three groups (p=0.163) (Table 2). 
Survival Analyses 
In univariate analysis, increased age was the only significant risk factor for death (HR 1.19, 95% CI 1.02-
1.38, P=0.028). Black race, mastectomy, higher stage, a positive SLN, and having an ALND were all risks for worse 
survival, but none of these reached statistical significance (Table 4). 
Discussion 
Several prospective studies with long-term follow-up have demonstrated equivalent outcomes with 
mastectomy or breast conservation in women with breast cancer.  As many of these studies excluded elderly women, 
retrospective population-based studies have been performed to assess the effect of treatment type and age on 
outcomes of patients undergoing treatment for breast cancer. In most of these studies, overall and disease-specific 
survival was noted to be improved in women undergoing breast conservation.24-25 We showed that octogenarians and 
nonagenarians with early-stage breast cancer undergoing breast-conserving surgery with or without radiation have 
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equivalent survival to patients having a mastectomy. Additionally, adjuvant radiation therapy adds no survival 
benefit over lumpectomy alone. In univariate analysis, age was the only factor that significantly decreased survival. 
Schonberg et al. proposed the identification of specific tumor factors and patient characteristics that may help 
identify elderly patients who may benefit from more aggressive treatment and those who may not as age was a 
stronger predictor than comorbidity in both survival and in determining the type of treatment a patient received.12  
Our previous study of 1,784 women older than 70 years in the SEER database noted improved overall and 
breast cancer-specific survival in women undergoing lumpectomy with or without radiation in comparison to those 
undergoing mastectomy. However, when adjusting for age, tumor size, lymph node status, race, comorbidities, and 
performance status (ability to perform ADLs), we noted that the type of surgery was not an independent factor 
determining survival.18 In this older cohort treated at our institution, we also found that type of local treatment did 
not impact survival.  
The question of whether lymph node status should be routinely assessed for elderly patients with early-
stage breast cancer has been debated in the literature. In our cohort, 85% of patients underwent SLN mapping and 
16.3% had an ALND. The International Breast Cancer Study Group Trial 10-93, which randomized women 60 years 
and older with clinically node-negative breast cancer to surgery with axillary clearance plus tamoxifen or surgery 
alone plus tamoxifen, found no difference in overall or disease-free survival. Additionally, the no axillary surgery 
arm group had an improvement in early quality of life.26-27 This has led to the argument that because nodal status is 
potentially less relevant in determining the need for adjuvant systemic chemotherapy for hormone receptor (HR)-
positive early-stage breast cancer in older women, axillary dissection or sentinel node biopsy to determine nodal 
status could arguably be avoided. Conversely, Hieken, Nettnin, and Velasco found that the results of SLN biopsy at 
their institution changed nonsurgical adjuvant treatment plans in 38% of 104 patients over the age of 65.28 We found 
that patients with a positive SLN for malignancy or who underwent an axillary dissection had no increased risk of 
death. The majority of our patients underwent axillary staging, however, the SLN was positive in less than a quarter. 
Of the 19 patients with positive SLN, 12 went on to have completion ALND, 7 of whom had a nodal status greater 
than N1 (metastases in 4 or more lymph nodes). This study did not specifically look at whether knowledge of nodal 
status changed adjuvant treatment. Based on these results and our current study, we cannot make a conclusion 
regarding the relativity of determining nodal status in the treatment of older women with early-stage breast cancer. 
Further studies should look at the influence of nodal staging on treatment decisions. 
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We found no difference in survival in octogenarians and nonagenarians with early-stage breast cancer who 
underwent lumpectomy with or without radiation therapy. This confirms Hughes’ et al. Cancer and Leukemia Group 
B (CALGB) 9343 study which examined 636 women over the age of 70 with clinical T1N0M0 estrogen receptor 
(ER)-positive breast carcinoma treated by lumpectomy who were randomly assigned to receive tamoxifen plus 
radiation therapy or tamoxifen alone. At ten year follow-up, they found the previously observed small improvement 
in locoregional recurrence with the addition of radiation therapy remains; however, this did not translate into an 
advantage in overall survival, distant disease-free survival, or breast preservation.29-32 An earlier study by Fyles et al. 
of 769 women age 50 years and older with T1-2N0M0 HR-positive breast cancers demonstrated that radiotherapy 
plus tamoxifen significantly reduces the risk of locoregional recurrence but has no impact on distant metastases or 
overall survival.33 Similarly, the PRIME II trial examined 1,326 women over the age of 65 with pathologic T1-
2N0M0 HR-positive breast cancer randomized to whole-breast radiotherapy plus endocrine therapy or endocrine 
therapy alone. The study found no differences between the two groups in terms of locoregional recurrence, distant 
metastases, contralateral breast cancers, new breast cancers, disease-free survival, or overall survival, and thus 
concluded that the addition of radiotherapy is not necessary for low-risk women.34 Martelli et al. looked at tumor 
size and the addition of radiotherapy to lumpectomy to patients with pT1 versus pT2 tumors. They studied 1,451 
patients with clinically node-negative breast cancer who all received hormone therapy despite hormone receptor 
status. They found that ipsilateral breast tumor recurrence (IBTR), distant metastasis, and breast cancer mortality 
were no different for pT1 patients whether or not they received radiation therapy, however, IBTR was significantly 
higher in the pT2 patients who did not receive radiation therapy while distant metastasis and breast cancer mortality 
were no different.35 In our cohort, we saw no difference in locoregional recurrence or distant metastasis between the 
three groups or when radiation therapy was added to lumpectomy. Current NCCN guidelines state that adjuvant 
radiation therapy may be omitted in select older patients, however, careful attention should be paid to omitting it in 
patients with large tumors or those at risk for being nonadherent to anti-estrogen therapy.6 
Elderly patients with HR-positive breast cancers may benefit from adjuvant anti-estrogen therapy. Both 
tamoxifen and AIs reduce the risk of recurrence and breast cancer-specific mortality.7, 30, 32, 36-37 AIs are slightly more 
effective than tamoxifen in terms of disease-free survival, however, the elderly are subject to their side effects of 
myalgias, arthralgias, bone pain, osteoporosis, and hot flashes.14, 30 Other adverse events of anti-estrogen therapy are 
increased risk of fracture, thrombotic events, and endometrial cancer.7 Treatment with anti-estrogen therapy can 
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reduce the risk of local recurrence whether or not a patient undergoes radiation therapy, however, the improvement 
in regional control and survival are dependent on treatment adherence.38 
Nonadherence to anti-estrogen therapy has been reported as high as 51% in the literature and shown to be 
related to worse outcomes.36-39 Most early discontinuation occurs within the first year of treatment.37 Older age is 
associated with poor adherence to hormone therapy over time.7, 36, 38, 40 Frailty is associated with noninitiation of 
hormone therapy, however, it does not seem to be related to nonadherence.36 Reasons cited for hormone therapy 
nonadherence are adverse side effects, financial constraints, and development of a second malignancy. We saw a 
55.3% incidence of anti-estrogen therapy nonadherence in our cohort. The most common reasons for early 
discontinuation were bony in nature (arthralgias, bone pain, worsening osteoporosis, and fractures) followed by 
functional decline, fatigue, and weakness; neurologic side effects; and development of endometrial thickening, 
disease progression, or a second malignancy during treatment course. Less common were hot flashes, incontinence, 
and financial reasons. Despite the fact that two-thirds of our elderly patients took anti-estrogen therapy and less of 
half of these were compliant with a five-year treatment course, age was the only factor that increased a patient’s risk 
of death. 
Literature shows that chemotherapy improves survival in older breast cancer patients and that more 
aggressive chemotherapy improves disease-free survival and overall survival in node-positive disease regardless of 
age.7, 41-42 Despite this benefit, older patients experience higher rates of chemotherapy-related toxicity due to frailty, 
decreased functional status, decreased renal clearance, and diminished bone marrow reserve.7 Older age is 
associated with nonuse of chemotherapy or deviation from chemotherapy guidelines.7, 17 In our cohort, 7 patients 
(7.6%) received chemotherapy. Of the 16 patients who had Her2/neu receptor-positive tumors, 5 (31.3%) received 
trastuzumab. 
There are several limitations of our retrospective cohort study. First, it is from a single tertiary academic 
institution, which limits its generalizability. Second, the relatively small sample size gives less statistical power, 
which limits the ability to detect differences between the groups. 
Conclusion 
Despite these limitations, our study is one of the few in the literature to examine the surgical outcomes in 
octogenarians and nonagenarians. Most elderly patients with early-stage breast cancer in this age group choose to 
undergo a lumpectomy without radiation. Octogenarians and nonagenarians with early-stage breast cancer 
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undergoing breast-conserving surgery with or without radiation have equivalent survival to patients having a 
mastectomy. In this age group, there is no difference in locoregional recurrence, distant metastasis, or breast-cancer 
related death between patients undergoing mastectomy or breast-conserving surgery without or without radiation. 
Despite the fact that less than half of patients are adherent to anti-estrogen therapy, survival is dependent on age 
rather than tumor factors, lymph node involvement, or local control. The addition of radiation therapy to 
lumpectomy adds no survival benefit and may be omitted in select patients.   
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TABLE 1. Demographic and clinicopathologic characteristics of patients, stratified by stage 
 Overall (n=92) Stage 0 (n=10) Stage I (n=53) Stage II (n=19) Stage III (n=10)  
Variable n/median %/SD n/median %/SD n/median %/SD n/median %/SD n/median %/SD p value 
Age (years)* 82 (80-94) 2.96 82 (80-86) 2.01 82 (80-91) 2.77 84 (80-94) 3.68 81.5 (80-89) 3.13 0.865 
Race            
White 81 88.0 7 70.0 7 88.7 17 89.5 10 100.0 0.442 
Black 10 10.9 3 30.0 5 9.4 2 10.5 0 0.0 
Other 1 1.1 0 0.0 1 1.9 0 0.0 0 0.0 
Method of dx            
Palpable  34 37.0 4 40.0 14 26.4 9 47.4 7 70.0 0.017 
Mammogram 54 58.7 5 50.0 38 71.7 9 47.4 2 20.0 
Ultrasound 3 3.3 1 10.0 1 1.9 1 5.3 0 0.0 
CT scan 1 1.1 0 0.0 0 0.0 0 0.0 1 10.0 
* Median (range) 
Abbreviations: SD = standard deviation; dx = diagnosis 
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TABLE 2. Demographic and clinicopathologic characteristics of patients, stratified by treatment type 
 Overall (n=92) Mastectomy (n=24) Lumpectomy with 
radiation (n=22) 
Lumpectomy alone 
(n=46) 
 
 
p value Variable n/median %/SD n/median %/SD n/median %/SD n/median %/SD 
Age (years)* 82 (80-94) 2.96 82 (80-94) 3.64 81 (80-89) 2.70 82 (80-91) 3.71 0.159 
Race          
White 81 88.0 21 87.5 21 95.8 39 84.8 0.688 
Black 10 10.9 3 12.5 1 4.5 6 13.0 
Other 1 1.1 0 0.0 0 0.0 1 2.2 
Stage          
0 10 10.9 2 8.3 1 4.5 7 15.2 0.011 
I 53 57.6 11 45.8 10 45.5 32 69.6 
II 19 20.7 5 20.8 7 31.8 7 15.2 
III 10 10.9 6 25.0 4 18.2 0 0.0 
T stage          
Tis 9 9.8 2 8.3 0 0.0 7 15.2 0.018 
T1 64 69.6 14 58.3 17 77.3 33 71.7  
T2 13 14.1 3 12.5 4 18.2 6 13.0  
T3 6 6.5 5 20.8 1 4.5 0 0.0  
N stage          
N0 71 77.2 15 62.5 13 59.1 43 93.5 0.013 
N1 13 14.1 5 20.8 5 22.7 3 6.5 
N2 5 5.4 3 12.5 2 9.1 0 0.0 
N3 3 3.3 1 4.2 2 9.1 0 0.0 
ER status          
Positive 72 78.3 16 66.7 17 77.3 39 84.8 0.217 
Negative 20 21.7 8 33.3 5 22.7 7 15.2 
Her2/neu status          
Positive 16 17.4 4 16.7 4 18.2 8 17.4 0.991 
Negative 76 82.6 20 83.3 18 81.8 38 82.6 
SLN bx performed          
Yes 78 84.8 20 83.3 21 95.5 37 80.4 0.265 
No 14 15.2 4 16.7 1 4.5 9 19.6 
SLN positive          
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Yes 19 24.4 6 30.0 8 38.1 5 13.5 0.088 
No 59 75.6 14 70.0 13 61.9 32 86.5 
ALND performed          
Yes 15 16.3 7 29.2 6 27.3 2 4.3 0.008 
No 77 83.7 17 70.8 16 72.7 44 95.7 
Recurrence          
Yes 
Locoregional 
Distant 
11 
5 
6 
12.0 
5.4 
6.5 
4 
2 
2 
16.6 
8.3 
8.3 
2 
0 
2 
9.1 
0.0 
9.1 
5 
3 
2 
10.8 
6.5 
4.3 
0.657 
No 81 88.0 20 83.3 20 90.9 41 89.1 
Death due to breast 
cancer 
         
Yes 3 3.3 2 8.3 1 4.5 0 0.0 0.163 
No 89 96.7 22 91.7 21 95.5 46 100.0 
* Median (range) 
Abbreviations: SD = standard deviation; ER = estrogen receptor; SLN = sentinel lymph node; bx = biopsy; ALND = axillary lymph node 
dissection 
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TABLE 3. Reasons for nonadherence to anti-estrogen therapy (tamoxifen or aromatase inhibitor) 
 
 
Reason for nonadherence 
n=26  
(n/%) 
Bony (osteoporosis, arthralgias, bone pain, fractures) 11 (42.3) 
Fatigue, weakness, functional decline 5 (19.2) 
Neurologic side effects 3 (11.5) 
Endometrial thickening, disease progression, second malignancy 3 (11.5) 
Hot flashes 2 (7.7) 
Financial 1 (3.9) 
Incontinence 1 (3.9) 
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TABLE 4. Univariate Cox models for overall survival 
 
 
Variables 
Univariate Models 
HR 95% CI p value 
Age 1.19 1.02 – 1.38 0.028 
Race*    
White    
Black 1.43 0.41 – 5.00 0.527 
Type of surgery    
Lumpectomy + XRT    
Lumpectomy alone 0.92 0.27 – 3.14 0.890 
Mastectomy 1.95 0.64 – 5.94 0.240 
Stage    
0    
I 0.97 0.20 – 4.75 0.969 
II 1.61 0.32 – 7.99 0.563 
III 1.49 0.27 – 8.22 0.649 
SLN bx performed    
No    
Yes 0.36 0.10 – 1.32 0.123 
SLN positive    
No    
Yes 1.93 0.77 – 4.81 0.160 
ALND    
No    
Yes 1.36 0.51 – 3.59 0.539 
Her2/neu status    
Negative    
Positive 1.32 0.27 – 6.55 0.737 
* Latin American excluded due to low numbers 
Abbreviations: HR = hazard ratio; CI = confidence interval; XRT = radiation therapy; SLN = sentinel lymph node; bx = biopsy; ALND = axillary 
lymph node dissection 
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FIG 1. Distribution of patients by stage 
 
 
 
FIG 2. Distribution of patients by stage, stratified by surgery type 
 
 
 
FIG 3. Incidence of recurrence and breast cancer-related death, stratified by surgery 
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